Meet IAG’s Bio-Partnering Team at Jefferies Virtual Healthcare Conference, 2020
IAG’s team will be attending Jefferies Virtual Healthcare Conference, 17-19 Nov 2020, who objective is to meet clinical stage biotech companies developing novel treatments to address patients’ needs.
IAG’s Bio-Partnering team is focused on building a diversified portfolio of innovative life science companies at various stages of clinical development. We have secured 13 partnerships to date, which include 2 blue chip pharma companies and 11 biotech and research companies.
‘At IAG, by bringing strategic collaborators and smart investments, we support novel drug or technology development efforts through conceptualisation, clinical trials to market entry’, said David Chia, IAG’s Head of Bio-Partnering.
Collaboratively, with the best academics of our time we are building mechanisms for early visibility of study performance through our DYNAMIKA platform. When needed and at the right time, our venture partners and analysts support development of the tailored strategies for potential M&As.
‘Our portfolio companies take full advantage of a wide range of IAG’s innovative R&D solutions, operational breadth and expertise, risk-sharing financing and partnership models’, added Dr. Diana Dupont-Roettger, AIG’s Chief Scientific Alliance Officer
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immuno-oncology, oncology, inflammation, rheumatology, musculoskeletal, rare diseases, neuro-degenerative and immunology markets.
More on our recent partnerships can be found here: https://wp1.ia-grp.com/trial-solutions/bio-partnering/
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin